Ahmed Hashem Fathallah Abdelrahman

Dr. Ahmed Hashem Fathallah Abdelrahman


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2023 in The Foot
Verified
Journal Article
Closed access
TATourki Abdulmhsen Almutairi
Tourki Abdulmhsen Almutairi
KRKhaled Mohamed Ragab
Khaled Mohamed Ragab
SESarah Makram Elsayed
Sarah Makram Elsayed
AEAhmed Bostamy Elsnhory
Ahmed Bostamy Elsnhory
MEMahmoud M. Elhady
Mahmoud M. Elhady
AAAhmed Hashem Fathallah Abdelrahman
Ahmed Hashem Fathallah Abdelrahman

16 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMohammed Alsabri
Mohammed Alsabri
AEAlaa Ahmed Elshanbary
Alaa Ahmed Elshanbary
ANAnas Nourelden
Anas Nourelden
AAAhmed Hashem Fathallah Abdelrahman
Ahmed Hashem Fathallah Abdelrahman
MZMohamed Sayed Zaazouee
Mohamed Sayed Zaazouee
LALita Aeder
Lita Aeder
Objective: This study aimed to assess and determine the presentation, risk factors, and outcomes of pediatric patients who were admitted for cardiac-related chest pain. Background: Although chest pain is common in children, most cases are due to non-cardiac etiology. The risk of misdiagnosis and the pressure of potentially adverse outcomes can lead to unnecessary diagnostic testing and overall poorer patient experiences. Additionally, this can lead to a depletion of resources that could be better allocated towards patients who are truly suffering from cardiac-related pathology. Methods: This review was conducted per PRISMA guidelines. This systematic review used several databases including MEDLINE, Embase, Scopus, and Web of Science to obtain its articles for review. Results: A total of 6,520 articles were identified, and 11 articles were included in the study. 2.5% of our study population was found to have cardiac-related chest pain (prevalence = 0.025, 95% CI [0.013, 0.038]). The most commonly reported location of pain was retrosternal chest pain. 97.5% of the study population had a non-cardiac cause of chest pain, with musculoskeletal pain being identified as the most common cause (prevalence = 0.357, 95% CI [0.202, 0.512]), followed by idiopathic (prevalence = 0.352, 95% CI [0.258, 0.446]) and then gastrointestinal causes (prevalence = 0.053, 95% CI [0.039, 0.067]). Conclusions: The overwhelming majority of pediatric chest pain cases stem from benign origins. This comprehensive analysis found musculoskeletal pain as the predominant culprit behind chest discomfort in children. Scrutinizing our study cohort revealed that retrosternal chest pain stands as the unequivocal epicenter of this affliction. Thorough evaluation of pediatric patients manifesting with chest pain is paramount for the delivery of unparalleled care, especially in the context of potential cardiac risks in the emergency department.

1 August 2023 in Canadian Journal of Respiratory Therapy
Verified
Journal Article
Open access
PDF file
YBYasra Badi
Yasra Badi
MHMohamed Hammad
Mohamed Hammad
ATAbdelrahman G. Tawfik
Abdelrahman G. Tawfik
MEMona Muhe Eldeen Eshag
Mona Muhe Eldeen Eshag
MEMahmoud M. Elhady
Mahmoud M. Elhady
AAAhmed Hashem Fathallah Abdelrahman
Ahmed Hashem Fathallah Abdelrahman
Background: More than six million people died due to COVID-19, and 10-15% of infected individuals suffer from post-covid syndrome. Corticosteroids are widely used in the management of severe COVID-19 and post-acute COVID-19 symptoms. This study synthesizes current evidence of the effectiveness of inhaled corticosteroids (ICS) on mortality, hospital length-of-stay (LOS), and improvement of smell scores in patients with COVID-19. Methods: We searched Embase, Web of Science, PubMed, Cochrane Library, and Scopus until Aug 2022. The Cochrane risk of bias tool was used to assess the quality of studies. We evaluated the effectiveness of ICS in COVID-19 patients through measures of mortality, LOS, alleviation of post-acute COVID-19 symptoms, time to sustained self-reported cure, and sense of smell (visual analog scale (VAS)). Results: Ten studies were included in the meta-analysis. Our study showed a significant decrease in the LOS in ICS patients over placebo (MD = -1.52, 95% CI [-2.77 to -0.28], p-value = 0.02). Patients treated with intranasal corticosteroids (INC) showed a significant improvement in VAS smell scores from week three to week four (MD =1.52, 95% CI [0.27 to 2.78], p-value = 0.02), and alleviation of COVID-related symptoms after 14 days (RR = 1.17, 95% CI [1.09 to 1.26], p-value < 0.0001). No significant differences were detected in mortality (RR= 0.69, 95% CI [0.36 to 1.35], p-value = 0.28) and time to sustained self-reported cure (MD = -1.28, 95% CI [-6.77 to 4.20], p-value = 0.65). Conclusion: We concluded that the use of ICS decreased patient LOS and improved COVID-19-related symptoms. INC may have a role in improving the smell score. Therefore, using INC and ICS for two weeks or more may prove beneficial. Current data do not demonstrate an effect on mortality or time to sustained self-reported cure. However, the evidence is inconclusive, and more studies are needed for more precise data.

16 July 2025 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
ANAnas Zakarya Nourelden
Anas Zakarya Nourelden
MMMohamed Mamdouh
Mohamed Mamdouh
IKIbrahim Kamal
Ibrahim Kamal
OAOsama Khalid Abdelgawad Ahmed
Osama Khalid Abdelgawad Ahmed
AEAdel Reda Abd Elwahab
Adel Reda Abd Elwahab
AAAhmed Hashem Fathallah Abdelrahman
Ahmed Hashem Fathallah Abdelrahman

1 September 2024 in Therapeutic Hypothermia and Temperature Management
Verified
Journal Article
Closed access
AMAli Mir
Ali Mir
MRMohammed Faraaz Rahman
Mohammed Faraaz Rahman
KRKhaled Mohamed Ragab
Khaled Mohamed Ragab
AAAhmed Hashem Fathallah Abdelrahman
Ahmed Hashem Fathallah Abdelrahman
SDShaden Daloub
Shaden Daloub
RKRaheel Khan
Raheel Khan
The study aims to compare the use of hypothermia in patients with myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI) with control. We systematically searched four electronic databases until March 2022. The inclusion criteria were any study design that compared hypothermia in patients with MI undergoing PCI with control. The risk of bias assessment of the included randomized controlled trials was conducted through Cochrane Tool, while the quality of the included cohort studies was assessed by the NIH tool. The meta-analysis was performed on RevMan. A total of 19 studies were entered. Regarding the mortality, there were nonsignificant differences between hypothermia and control (odds ratio [OR] = 1.06, 95% confidence interval [CI] 0.75 to 1.50, p = 0.73). There was also no significant difference between the control and hypothermia in recurrent MI (OR = 1.21, 95% CI 0.64 to 2.30, p = 0.56). On the other hand, the analysis showed a significant favor for hypothermia over the control infarct size (mean difference = −1.76, 95% CI −3.04 to −0.47, p = 0.007), but a significant favor for the control over hypothermia in the overall bleeding complications (OR = 1.88, 95% CI 1.11 to 3.18, p = 0.02). Compared with the control, hypothermia reduced the infarct size of the heart, but this finding was not consistent across studies. However, the control had lower rates of bleeding problems. The other outcomes, such as death and the incidence of recurrent MI, were similar between the two groups.

29 September 2026 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
EREhsan Rojhani
Ehsan Rojhani
CSClaudio V. Schenone
Claudio V. Schenone
AAAhmed Hashem Fathallah Abdelrahman
Ahmed Hashem Fathallah Abdelrahman
NZNikan Zargarzadeh
Nikan Zargarzadeh
AHAkihiro Hasegawa
Akihiro Hasegawa
ASAlireza A. Shamshirsaz
Alireza A. Shamshirsaz